CA3075784C - Methodes de traitement du cancer du sein triple negatif comprenant un agent inhibiteur de cdk19 - Google Patents

Methodes de traitement du cancer du sein triple negatif comprenant un agent inhibiteur de cdk19

Info

Publication number
CA3075784C
CA3075784C CA3075784A CA3075784A CA3075784C CA 3075784 C CA3075784 C CA 3075784C CA 3075784 A CA3075784 A CA 3075784A CA 3075784 A CA3075784 A CA 3075784A CA 3075784 C CA3075784 C CA 3075784C
Authority
CA
Canada
Prior art keywords
cdk19
cells
agent
cdk8
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3075784A
Other languages
English (en)
Other versions
CA3075784A1 (fr
Inventor
Michael F. Clarke
Robert W. Hsieh
Original Assignee
Leland Stanford Junior University
CZ Biohub SF LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University, CZ Biohub SF LLC filed Critical Leland Stanford Junior University
Priority claimed from PCT/US2018/051489 external-priority patent/WO2019055977A1/fr
Publication of CA3075784A1 publication Critical patent/CA3075784A1/fr
Application granted granted Critical
Publication of CA3075784C publication Critical patent/CA3075784C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

L'invention concerne des méthodes de traitement du cancer du sein triple négatif (TNBC) chez le patient par administration au patient d'un agent qui inhibe l'expression ou l'activité de la kinase-19 cycline-dépendante (CDK19). Dans certains modes de réalisation, l'agent peut être un inhibiteur de type petite molécule, un polynucléotide (par exemple, un ARNsh, un ARNsi), ou une protéine (par exemple un anticorps). Dans certains modes de réalisation, l'agent n'inhibe pas l'activité ou l'expression de la CDK8.
CA3075784A 2017-09-18 2018-09-18 Methodes de traitement du cancer du sein triple negatif comprenant un agent inhibiteur de cdk19 Active CA3075784C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762560140P 2017-09-18 2017-09-18
US62/560,140 2017-09-18
PCT/US2018/051489 WO2019055977A1 (fr) 2017-09-18 2018-09-18 Méthodes de traitement du cancer du sein triple négatif

Publications (2)

Publication Number Publication Date
CA3075784A1 CA3075784A1 (fr) 2019-03-21
CA3075784C true CA3075784C (fr) 2025-11-25

Family

ID=

Similar Documents

Publication Publication Date Title
JP7392954B2 (ja) トリプルネガティブ乳癌の治療方法
Shi et al. Circular RNA ANAPC7 inhibits tumor growth and muscle wasting via PHLPP2–AKT–TGF-β signaling axis in pancreatic cancer
Chen et al. Circular RNA circRHOBTB3 represses metastasis by regulating the HuR-mediated mRNA stability of PTBP1 in colorectal cancer
Li et al. LncRNA PRADX-mediated recruitment of PRC2/DDX5 complex suppresses UBXN1 expression and activates NF-κB activity, promoting tumorigenesis
US20160024597A1 (en) miRNAs AS THERAPEUTIC TARGETS IN CANCER
US10301684B2 (en) Treatment of angiogenesis disorders
JP2017518764A (ja) 癌の処置のための多標的指向ＲＮＡｉ
JP5931897B2 (ja) マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法
EP3134528A1 (fr) Arni à cibles multiples permettant le traitement de cancers
Peng et al. CircFAT1 promotes lung adenocarcinoma progression by sequestering miR-7 from repressing IRS2-ERK-mediated CCND1 expression
Li et al. Epigenetic upregulation of HOXC10 in non-small lung cancer cells
JP5611953B2 (ja) 癌の処置における治療標的としてのチロシンキナーゼ受容体ｔｙｒｏ３
KR101514877B1 (ko) ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
CA3075784C (fr) Methodes de traitement du cancer du sein triple negatif comprenant un agent inhibiteur de cdk19
CA2932910A1 (fr) Methodes de diagnostic et de traitement de cancer metastatique
US20230104563A1 (en) Method for identifying targets for precision cancer therapy
AU2022200547A1 (en) Method for identifying targets for precision cancer therapy
US20250340946A1 (en) Method of prognosing and treating glioma
Smink Alternative Splicing, a Driving Force in Acute Myeloid Leukaemia and How to Target it
CN107456582B (zh) microRNA-1254及其种子基序和非种子序列在抑制肿瘤恶性增殖中的应用
Singh et al. Modulating populational variance of methyl-guanine methyl transferase expression through miR-181d degradation: a novel mechanism of temozolomide resistance
CN121987656A (zh) circVEGFC在横纹肌肉瘤治疗中的用途
CA3130929A1 (fr) Methode pour determiner des cibles pour la cancerotherapie de precision
HK1245330B (en) Method for identifying nucleic acids regulating metastasation
HK1193429B (en) Treatment of angiogenesis disorders